Physician
Hematology
Dr. Michael B. Maris, MD
|
|
Give Review
Michael Maris works in the field of Hematology. He went to Perelman School of Medicine at the University of Pennsylvania. Dr. Michael B. Maris is also published. He has 76 publications published. The lastest publication: "Reduced IL-2 expression upon antigen stimulation is accompanied by deficient IL-9 gene expression in T cells of patients with CVID.' Michael B. Maris, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
- Joint Analysis of BICEP2/Keck Array and Planck Data.
- A phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia.
- REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
- A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.
- Pre-transplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.
- Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
- Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
- Nonmyeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high risk acute lymphoblastic leukemia.
- Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.
- Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hemat...
- Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
- Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for ...
- Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disord...
- Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
- Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic ce...
- Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloab...
- Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
- Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning.
- Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell tran...
- Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of po...
- Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.
- Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
- Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
- HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia.
- Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation.
- Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
- Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.
- Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.
- Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
- Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors.
- Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of...
- Acute renal failure after nonmyeloablative hematopoietic cell transplantation.
- Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.
- Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation.
- HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
- Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning.
- Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
- Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
- Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.
- Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a m...
- Reduced IL-2 expression upon antigen stimulation is accompanied by deficient IL-9 gene expression in T cells of patients with CVID.
- Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
- Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype ...
- Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial.
- Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgraf...
- Outpatient allografting in hematologic malignancies and nonmalignant disorders--applying lessons learned in the canine model to humans.
- Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century.
- Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives.
- Non-myeloablative hematopoietic stem cell transplantation.
- Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.
- Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
- Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
- Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
- Type of post-grafting immunosuppression after non-myeloablative blood cell transplantation may influence risk of delayed haemolysis due to minor ABO incompatibility.
- Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.
- Reduced toxicity and prompt engraftment after minimal conditioning of a patient with Fanconi anemia undergoing hematopoietic stem cell transplantation from an HLA-matc...
- Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning.
- The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases.
- Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation.
- Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning.
- Lessened severe graft-versus-host after "minitransplantations".
- Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
- Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation.
- Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients.
- Optimization of allogeneic transplant conditioning: not the time for dogma.
- Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a re...
- Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning.
- High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after ...
- Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission.
- Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation.
- Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome.
- Prognostic relevance of ''early-onset'' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation.
- Allogeneic hematopoietic cell transplantation as consolidation immunotherapy of cancer after autologous transplantation.
Schools
University Of Pennsylvania School Of Medicine
Oregon Health and Science University Hospital
Hutchinson Cancer Research CenterUniversity
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Doctors Specialties
- Hematology
Accepted Insurances
Education
-
University of Washington -
Oregon Health & Science University -
Perelman School of Medicine at the University of Pennsylvania
Drug Facts
| NPI NUMBER | 1053395624 | |
| NPPES Provider LastName | MARIS | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 802181238 | |
| NPPES Provider State | CO | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1031.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 18.0 | |
| Percent Opioid Claims | 1.75 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1053395624 |
| Last Name Of The Provider | MARIS |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
Dr. Mark W. Brunvand, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Meghan S. Liel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Teresa M. Launder, MD
This Doctor is OpenDoctor Recommended.
|